Secretary of the National Pharmacovigilance Committee. Deputy Head of Adverse Drug Reactions Dept

Similar documents
Secretary of the National Pharmacovigilance Committee. Deputy Head of Adverse Drug Reactions Dept

Update on SCOPE - Strengthening Collaborations to. Operate Pharmacovigilance in Europe

EudraVigilance auditable requirement project

Overview of the new pharmacovigilance legislation

PCWP and HCPWP work programmes for 2013

Head of Electronic Data Management Section. National Organisation for Medicines (EOF) (Greece) Populating and Updating EOF s database.

ENCePP Plenary: New Pharmacovigilance legislation

Functioning of the PRAC

Explanatory Note to GVP Module VII

PHARMACOVIGILANCE IN AND EMERGING MARKETS: AN INDUSTRY PERSPECTIVE. Shashidhar Swamy (Head, Pharmacovigilance) Wockhardt limited, Mumbai

Signal Management in the EU and future extended access to EudraVigilance for industry

Recent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency

Marketing Authorisation Routes in the EU

Topic 5: Competency Authors: Jelena Ivanovic; Marco Di Girolamo (Version 4 June 2015)

The EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines

New pharmacovigilance systems and services

Implementing the New Pharmacovigilance Legislation

Di Renzo Regulatory Affairs ROME - MILAN - LONDON

EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia

The new Pharmacovigilance legislation and implementation planning

Three years of the Pharmacovigilance Risk Assessment Committee Where are we now?

Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety

Need for collaboration in pharmacovigilance to ensure effective health protection and promotion

Update on preparation for Signal Management

In this video you will hear about pharmacovigilance, what it means and the role of the European Medicines Agency

EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9).

Information on the Member States requirement for the nomination of a pharmacovigilane (PhV) contact person at national level

How are medicines evaluated at the EMA

EudraVigilance: Preparing for Change

Research and Innovation in Drug Discovery and Diagnostics

Questions And Answers To Support The

OMICS Group. Contact us at:

Pharmacovigilance: Information systems and services

HOT TOPICS IN PV. Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva

PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use

Review of three years of Post Authorization Safety Studies (PASS) landscape under the 2010 European Pharmacovigilance

Importance of Pharmacovigilance for Pharmaceutical Industry

Work plan for the CVMP Pharmacovigilance Working Party (PhVWP-V) 2018

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?

EudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables

Core member of a Biocidal Products Committee Working Group

2008 Pharmaceutical Package - Impact on Implementation by BfArM

Applies to: Signal Management Leads in the Signal Management service (P-PH-SMA) and personnel in the Learning and Development service (A-HR-LAD).

Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA

IMI WEB-RADR (recognising adverse reactions) project: goals and current activities

8 th Kitasato- Harvard Symposium

BULGARIAN ASSOCIATION FOR DRUG INFORMATION (BADI)

New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar

PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group

Pharmacovigilance. An agency of the European Union

Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports

SCOPE Work Package 8 Lifecycle Pharmacovigilance. PSUR/PSUSA and Referral Recommendations

FIRST YEAR PHARM. D. Know about the theory and their application in pharmacy PDM107 Remedial Mathematics

HOW CAN AN ADAPTIVE TRAINING PROGRAMME SUPPORT CHANGE IN ORGANISATIONAL STRATEGY? Dr Karine Palin

EMA pharmacovigilance system manual

Safety Measures in the new Pharmacovigilance System

EU Perspective on Regulatory Issues for Biologics

Wissenswertes aus dem Bereich PHV

What is an ideal PSUR? A new focus based on aligned expectations

Pharmacovigilance: Information systems and Services

A COURSE IN DRUG REGULATIONS Of the Bulgarian Association of Drug Information (BADI)

Clinical Trial Safety Reporting requirements

Telematics Governance

Regulatory Aspects of Pharmacovigilance

NIS Considerations - Bulgaria

Pharmacovigilance. Maia Uusküla

Q & A on PSUSA: Guidance document for assessors

Introduction to the Identification of Medicinal Products ( IDMP)

Safety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington

The PRAC Roles and challenges Focus on RMPs and RMAs. Prof. Jean-Michel Dogné. Head of the Department of Pharmacy PRAC effective member

CURRICULUM VITAE. Lecturer (Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al- Azhar University, Cairo, Egypt)

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EPSA EC CONSULTATION:

Multi-Criteria Drug Discovery: using CoMFA models to drive target specificity. Lei Wang, Ph.D.

Issues identified by stakeholders: follow-up from EMA s ATMP workshop

National Academic Reference Standards (NARS) Pharmacy. January st Edition

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017

Introduction to Drug Design and Discovery

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

The European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications

Russian Federation. Chapter 12. By Julianna Tabastajewa and Svetlana Rudevich

FIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution

Pharmacovigilance System Master file

Industry perspective: Non-prescription medicines

Cancer Vanguard. Biosimilars Trust Policy Template

Agenda Pharmacovigilance Inspectors Working Group Training Course

SIAPS assistance is grouped into four technical areas

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board

Feedback on EudraVigilance & new functionalities

RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018

The role of patients at the EMA

II.B.4. Information to be contained in the PSMF/ PSSF

Pharmacovigilance System in Russia and the EAEU

The interface between Good Clinical Practice and Good Manufacturing Practice

Track III: International Clinical Trials: Global Compliance Norms and EU Focus

The EU Market Environment for Biosimilar Medicines

A Study on Regulatory Requirements of Risk Management Plan for Pharmaceuticals in Europe, U.S. and Brazil

Transcription:

Curriculum vitae PERSONAL INFORMATION Agni Kapou WORK EXPERIENCE November 2011 March 2017 Secretarial and scientific management of the National Pharmacovigilance Committee monthly meetings. January 2017 Present Deputy Head of Adverse Drug Reactions Dept PV team management Legal issues of new employees in basic pharmacovigilance activities Evaluation of DHPCs Signal management PSUR assessment RMP Assessment PV promotion August 2015 Present Deputy Responsible for Quality Assurance of the Division of Pharmaceutical Studies & Research Maintenance of the Quality System of the Devision of the employees of the Devision May 2015 February 2016 Deputy Head of Adverse Drug Reactions Dept Preliminary and final evaluation of the incoming ADR reports Submission of ADR reports to EUDRAVIGILANCE Follow-Up communication with HCPs Evaluation of DHPCs and Educational Material (RMP) RMP Assessment of new employees on basic pharmacovigilance activities March 2014 January 2017 Deputy Head of National Formulary Dept Design and development of a new National Formulary 26/10/17 European Union, 2002-2017 http://europass.cedefop.europa.eu Page 1 / 5

October 2011 January 2017 Pharmacovigilance officer in the Adverse Drug Reaction Dept Preliminary and final evaluation of the incoming ADR reports Submission of ADR reports to EUDRAVIGILANCE Follow-Up communication with HCPs Evaluation of DHPCs and Educational Material (RMP) April 2001 October 2011 Government controller Ministry of Health - Public Health Insurance Organizations (OPAD-TYDKY, OAEE) (Greece) Control of good practice in prescribing and dispensing medicines and of pharmaceutical expenditure - Inspections in pharmacies (as private enterprises) or in clinics and hospitals January 2001 July 2001 Researcher in the Laboratory of Molecular Analysis in NHRF Ministry of Education - University of Ioannina and National Hellenic Research Foundation (NHRF) (Greece) Study of the molecular structure of NSAIDs (Oxicams) by NMR spectroscopy EDUCATION AND TRAINING March 2001 July 2007 PhD in Medicinal Chemistry (Drug Design) University of Patras (Departments of Pharmacy and Chemistry) - National Hellenic Research Foundation (Greece) Drug Design NMR spectroscopy Differential Scanning Calorimetry (DSC) Molecular Modeling 3D-Quantitative Structure Activity Relationships (3D-QSAR) September 1999 March 2001 Msc in Medicinal Chemistry (Conformational Analysis) University of Patras (Departments of Pharmacy and Chemistry) - National Hellenic Research Foundation (Greece) Synthesis NMR spectroscopy Molecular Modeling July 1999 July 1999 Professional license Ministry of Health (Greece) License for working as a pharmacist in Greece September 1994 July 1999 Degree in Pharmacy University of Athens - Department of Pharmacy (Greece) 26/10/17 European Union, 2002-2017 http://europass.cedefop.europa.eu Page 2 / 5

April 2012 April 2012 EUDRAVIGILANCE certificate EUDRAVIGILANCE use May 2013 May 2013 XEVMPD certificate Extended EV Medicinal Product Dictionary (XEVMPD) use November 2013 November 2013 January 2014 January 2014 PhV Inspectors EV and EVDAS EV and EVDAS use October 2014 October 2014 November 2015 November 2015 Assessor's training PSURs, Referrals, RMPs and Post Authorization studies assessment: Increase knowledge of what were the major scientific, regulatory and procedural updates in the last year and gain awareness trough discussion of relevant examples trough the lifecycle of the product. December 2015 December 2015 Signal Detection Workshop Current state of the art in terms of the science of signal detection, proposals for evidence based process improvements and to identification and discussion of current and future challenges. October 2016 October 2016 - BfArM October 2016 October 2016 EVDAS training for NCAs Signal detection and signal management September 2016 September 2016 PhV assessment (in scope WP8) Scope Joint Action (Portugal) RMP, PSUR, PASS assessment etc. 26/10/17 European Union, 2002-2017 http://europass.cedefop.europa.eu Page 3 / 5

November 2016 November 2016 Pharmacovigilance assessments challenges and solutions for pharmacovigilance assessors (United Kingdom) Share the experience in different procedures concerning a pharmacovigilance assessment, to identify best practice. December 2016 December 2016 Introduction to the Basics of Clinical Research National Organization for Medicines (EOF)-Clinical Trials Dept (Greece) CT Protocols approval procedures and CT Inspections. April 2017 April 2017 Pharmacovigilance training course 2017 (United Kingdom) RMP, PSUR, PASS assessment, Signal Management etc. April 2017 April 2017 Signal management additional training (in scope WP5) Scope Joint Action (Netherlands) Concepts of signal management process applied at member state level (Signal detection, prioritazation, validation, confirmation, etc.), focus on reports of special interest and practical exercises. October 2017 October 2017 EVDAS training (United Kingdom) Train the trainers in EVDAS (changes due to new Eudravigilance). ADDITIONAL INFORMATION Expertise Risk Management & Risk Communication Management and assessment of ADR reports Drug Design (Conformational Analysis, NMR Spectroscopy, 3D QSAR) Good practice in prescribing and dispensing medicines Publications International Journals Kapou A., Fousteris M., Nikolaropoulos S., Zervou M, Grdadolnik S., Zoumpoulakis P., Kyrikou I., Mavromoustakos T., 2D NMR and conformational analysis of a prototype anti-tumour steroidal ester, J. Pharm. Biomed. Analysis, (2005), 38, 428-434. Kapou A., Nikolaropoulos S., Siapi E. and Mavromoustakos T., Effects of steroidal carriers of alkylating agents on the phase transition in DPPC membrane bilayers, Thermochimica Acta, (2005),429,53-56. Kapou Α., Benetis Ν., Avlonitis Ν., Calogeropoulou Τ., Koufaki Μ., Scoulica Ε., Nikolaropoulos S., Mavromoustakos T., 3D-Quantitative Structure-Activity Relationships of Synthetic Antileishmanial Ring-Substituted Ether Phospholipids, Bioorg. Med. Chem., (2007) 15(3),1252-1265. Durdagi S., Kapou A., Kourouli T., Andreou T., Nikas SP., Nahmias VR., Papahatjis DP., Papadopoulos MG., Mavromoustakos T., The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1 position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2, J. Med Chem. (2007) 50(12),2875-85. Durdagi S., Koukoulitsa C., Kapou A., Kourouli T., Andreou T., Nikas S. P., Nahmias V. R. Papahatjis D. P., Testing the 3D-QSAR/CoMFA-CoMSIA results of flexible bioactive compounds with molecular docking studies, Drugs of the Future (2007) 32, 79-79. Kapou A., Benetis N.P., Durdagi S., Nikolaropoulos S., Mavromoustakos T., 3D QSAR/ CoMFA and 26/10/17 European Union, 2002-2017 http://europass.cedefop.europa.eu Page 4 / 5

CoMSIA studies on antileukeumic steroidal esters coupled with conformatioanally flexible nitrogen mustards, J. Chem. Inf. Mod. (2008), 48(11), 2254-64. Publications in Books and Electronic Journals Kapou A., Mavromoustakos T., Grdadolnik S. G.,Nikolaropoulos S., Synthesis and Conformational Analysis of Steroidal Carriers of Alkylating Agents with the Use of Two-Dimensional Nuclear Magnetic Resonance in Drug Discovery and Design: Medical Aspects, Part III (J. Matsoukas and T. Mavromoustakos, Eds), IOS Press, (2002), 167-173. Mavromoustakos T., Kyrikou I., Kapou A., Kovala Demertzi D., Effects of NSAIDs in Membrane Bilayers in Drug Discovery and Design: Medical Aspects, Part II (J. Matsoukas and T. Mavromoustakos, Eds), IOS Press, (2002), 167-173. Mavromoustakos Τ., Zoumpoulakis P., Zervou M., Kyrikou I., Kapou A., Benetis N., The Use of Computational Analysis to Design Novel Drugs, Proceedings of the International conference of Computational Methods in Science and Engineering (2003), ed. T.E.Simos, p.413-417. Mavromoustakos T., Kapou A., Benetis N.P., Zervou M., Conformational Analysis using 2D NMR Spectroscopy Coupled with Computational Analysis as an Aid in the Alignment Procedure of 3DQSAR Studies, Drug Des. Rev. - Online, (2004), 3, 235-245. E. Apostolidou, G. Aislaitner, L. Klironomos, A. Kapou, D. Kouvelas. The Impact of the New Pharmacovigilance Legislation on the Applications and Files Submitted To the Department of Adverse Drug Reactions of the National Organisation for Medicines in Greece (EOF), Poster presentation in the 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (2015) Projects Memberships Alternate member in the PhV Inspectors Working Group () Member in PRAC Other Relevant Information Languages Mother tongue: Greek Other: English (excellent), French (very good), Spanish (good) Computers ECDL certificate 26/10/17 European Union, 2002-2017 http://europass.cedefop.europa.eu Page 5 / 5